Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis

Phase 3 ADAPT SERON data at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago showed efgartigimod (Vyvgart) significantly improved MG-ADL scores in seronegative generalized Mysasthenia Gravis (gMG) patients, with an FDA priority review targeting May 10, 2026.

Mechanism of Action

Vyvgart operates through FcRn receptor blockade, reducing circulating immunoglobulin G (IgG) levels regardless of the specific IgG subclass driving disease. That mechanism-agnostic approach is part of why the ADAPT SERON results were consistent across the antibody subtypes studied. This unique mechanistic feature distinguishes it from more narrowly targeted agents in the gMG pipeline.

Why It Matters

Key Aspects of Seronegative Generalized Myasthenia Gravis

The key aspects of seronegative generalized Myasthenia Gravis (SNMG) include 1) diagnostic challenges, 2) specialized testing requirements, 3) established treatment pathways, and 4) prognosis and remission targets.

1) Diagnostic Overview

• Definition: Patients are considered seronegative when standard assays fail to detect typical antibodies, such as acetylcholine receptor antibody-seronegative (AChR) or muscle-specific tyrosine kinase (MuSK).
• Alternative Diagnoses: It is critical to reconsider the diagnosis in seronegative patients. Clinicians must rule out Congenital Myasthenic Syndromes (genetic), which may present even in patients aged 60+, as well as Lambert-Eaton Myasthenic Syndrome (LEMS), Amyotrophic Lateral Sclerosis (ALS), Miller Fisher Syndrome, or myopathies.

2) Specialized Testing and Pathophysiology

Cell-Based Assays (CBA): These are more sensitive than standard assays and should be used to confirm that a patient is truly seronegative.

• Electrophysiology:
• Repetitive Nerve Stimulation (RNS): A positive RNS (decrement) is unusual if the muscle is clinically normal.
• Single-Fiber EMG (SFEMG): This is a highly sensitive test for neuromuscular junction disorders but lacks specificity, as it can be abnormal in neurogenic or myopathic conditions.
• Broad Pathophysiology: Traditional therapies are often favored for seronegative MG because they cover a broader range of the disease’s potential (and sometimes unknown) pathophysiological mechanisms.

3) Treatment Strategies

• Foundational Therapy: Traditional immunotherapies remain the core treatment framework for seronegative patients.
• Symptomatic: Pyridostigmine.
• Immunosuppression: Corticosteroids and nonsteroidal immunosuppressive treatments (NSISTs), such as Azathioprine or Mycophenolate Mofetil.
• Rescue and Crisis Care: Seronegative patients in crisis still rely on IVIG and Plasma Exchange (PLEX).
• Biologics/Newer Agents: While newer targeted therapies (e.g., FcRn inhibitors, complement inhibitors) have expanded options, they are often studied and indicated specifically for AChR-positive populations.

4) Prognosis and Remission Targets

• Outcomes: Data from the Duke Registry suggest that outcomes among seronegative patients receiving traditional therapies are similar to those among seropositive patients.
• Targets: The goal remains Minimal Manifestation Status (MMS) or Minimal Symptom Expression (MSE). In a large cohort of 367 patients (including seronegative), 72% reached the treatment goal within 24 months of their first visit.

Before ADAPT SERON –> ADAPT+ Overview

This interim analysis of the ADAPT+ phase 3 study evaluates the long-term safety, tolerability, and efficacy of efgartigimod in adults with generalized myasthenia gravis (gMG). Efgartigimod is a human IgG1 antibody fragment that blocks the neonatal Fc receptor (FcRn), thereby reducing levels of pathogenic IgG autoantibodies.

Study Design and Population

ADAPT+ was an open-label, multicenter, three-year extension of the pivotal ADAPT study. Participants received 10 mg/kg intravenous infusions in cycles of four weekly doses. Subsequent treatment cycles were individualized based on clinical evaluation, with a minimum of four weeks between cycles. Of the 145 participants who received at least one dose, 111 (76.6%) were AChR-Ab+ and 34 (23.4%) were AChR-Ab-.

Safety and Tolerability

Over 217.6 participant-years of observation, efgartigimod was well tolerated.

• Adverse Events: 84.8% of participants reported at least one treatment-emergent adverse event (TEAE). The most frequent were headache (24.8%), COVID-19 (15.2%), and nasopharyngitis (13.8%).
• Infections: Most infections were mild to moderate, and their frequency did not increase with subsequent cycles.
• Fatalities: Five fatal TEAEs occurred, though none were considered treatment-related by investigators.
• Metabolic Markers: Unlike some other FcRn inhibitors, efgartigimod did not reduce serum albumin or increase cholesterol levels.

Efficacy & Pharmacodynamics

Efgartigimod demonstrated consistent and repeatable clinical improvements across multiple cycles.

• Clinical Improvement: Clinically meaningful improvements (CMI) in MG-ADL and QMG scores were observed as early as one week after the first infusion.
• Success Rates: In the first 10 cycles, over 90% of AChR-Ab+ participants achieved a CMI in MG-ADL scores (a reduction of >2 points). Similar efficacy was noted in AChR-Ab- participants.
• IgG Reduction: Maximum mean total IgG reductions (approximately 56%–60% in cycle 1) aligned with the timing of peak clinical improvement.
• Dosing Frequency: For AChR-Ab+ participants with at least one year of follow-up, the mean annualized rate was 4.7 cycles per year.

Conclusion

The interim results corroborate the substantial clinical benefits seen in the initial ADAPT study. The data support the long-term safety of efgartigimod and the effectiveness of an individualized dosing regimen for a broad population of gMG patients, regardless of their antibody status.

ADAPT SERON Clinical Trial Results

Results from the ADAPT SERON trial, presented at the 2026 AAN annual meeting, showed that efgartigimod alfa (Vyvgart) produced statistically significant improvements in adults with acetylcholine receptor antibody-seronegative (AChR−) generalized myasthenia gravis (gMG). The finding carries immediate regulatory weight. Argenx announced that a supplemental Biologics License Application (sBLA) for this population has received priority review from the Food and Drug Administration (FDA), with a target action date of May 10, 2026.

ADAPT SERON was a Phase 3, double-masked, placebo-controlled trial that met its primary endpoint (P=0.0068), demonstrating a statistically significant improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at Week 4 compared with placebo. Efgartigimod-treated patients achieved a mean MG-ADL reduction of 3.35, compared with 1.90 in placebo-treated patients. MG-ADL is a validated measure of disease activity in patients with myasthenia gravis that assesses the functional impact of symptoms on daily activities such as speaking, chewing, swallowing, breathing, and limb strength.

The open-label extension further showed that improvement was enhanced across subsequent treatment cycles, with consistent results across all three antibody-negative subgroups enrolled: MuSK-positive, LRP4-positive, and triple seronegative patients.

Who It Affects

patients

gMG is a rare, chronic, neuromuscular autoimmune disease caused by pathogenic IgGs targeting the neuromuscular junction (NMJ), resulting in impaired neuromuscular transmission and debilitating, potentially life-threatening muscle weakness and chronic fatigue. Approx. 80% of patients with gMG have detectable antibodies against the AChR in their sera (plural of serum), and these patients are diagnosed with AChR-Ab seropositive gMG.

Seronegative Patients

Nearly 20% of patients with gMG do not have detectable serum antibodies directed against AChR and are referred to as AChR-Ab seronegative gMG. These patients may have detectable autoantibodies targeting other NMJ proteins, such as muscle-specific tyrosine kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4), or other proteins. Anti-MuSK antibodies are detected in approximately 1-10% of patients with gMG, while anti-LRP4 antibodies are detected in approximately 1-5% of patients with gMG.

Triple Seronegative Patients

Approximately 10% of patients have no detectable autoantibodies against AChR, MuSK, or LRP4. Historically, triple seronegative patients have been excluded from studies and have a higher disease burden and unmet medical need compared to patients with detectable autoantibodies. Currently, no approved treatments are available for patients with anti-LRP4 antibodies or for triple seronegative patients.

Clinicians and the Healthcare System

Seronegative MG is poorly understood; however, clinicians are on the front lines, ensuring that patients with no detectable antibodies are diagnosed based on clinical presentation. A thorough patient review includes the medical history, electrodiagnostic findings, and responses to standard MG treatments, such as cholinesterase inhibitors. Additional research is being conducted to develop better treatments for this ultra-rare disease. Clinicians and healthcare systems should offer clinical trials to applicable and appropriate patients. Research care is patient care.

Managed Care Organizations

For managed care organizations, the timing matters. Seronegative patients represent roughly 10% to 15% of the gMG population, a cohort that has had no approved targeted biologic therapy. If the FDA approves the sBLA on schedule this spring, plans will have a narrow window between approval and real-world prescribing to establish coverage criteria, prior authorization pathways, and step-therapy frameworks.

Because Vyvgart is already on formulary for AChR-positive gMG in many plans, the seronegative expansion will likely be reviewed under existing specialty policy architecture rather than as a new molecular entity. Still, the clinical criteria will need to be updated to reflect the distinct antibody profile of this population.

What Changes

The sooner MG is treated, the better the chances of improvement. Most treatments for MG are FDA-approved only for patients who are ACHR antibody-positive. This list of approved drugs includes Soliris, Ultomiris, Vyvgart, and zilucoplan. As more drugs like Vyvgart demonstrate efficacy and safety in seronegative generalized Myasthenia Gravis and become FDA-approved, appropriate patients will no longer have to rely on off-label approvals or attempt the long process of applying for special approval through insurance.

Hope for Seronegative Patients

Prior to the ADAPT SERON clinical trial, seronegative generalized Myasthenia Gravis patients were not included in clinical trials and were left with few treatment options. Initial results of the ADAPT SERON trial demonstrated a statistically significant improvement in the MG-ADL total score compared with placebo (primary endpoint), with a clinically meaningful change from baseline, and that the trial was well tolerated in participants with AChR-Ab seronegative gMG.

As the ADAPT SERON clinical trial continues to monitor patients and the efficacy and safety of Vyvgart, patients, caregivers, and clinicians will, hopefully, soon have an FDA-approved treatment option.

References

1. Argenx SE. argenx brings neuromuscular leadership to AAN 2026 with new data supporting broader Vyvgart use across MG and CIDP. GlobeNewswire. April 18, 2026. https://www.globenewswire.com/news-release/2026/04/18/3276554/0/en/argenx-Brings-Neuromuscular-Leadership-to-AAN-2026-with-New-Data-Supporting-Broader-VYVGART-Use-Across-MG-and-CIDP.html
2. Howard JF Jr, Bril V, Vu T, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2024;14:1284444. Published 2024 Jan 17. doi:10.3389/fneur.2023.1284444
3. Howard JF, Guptill J, Jimenez RH, Gistelinck F, Steeland S. Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis (P7-11.032). Neurology. 2025;104(7\_Supplement\_1):2759. doi:10.1212/WNL.0000000000210564